TNFSF11 and osteoporosis: There are published studies in which the dynamics of upstream cells (e.g., accumulation and depletion) have been associated with clinically important issues in the treatment of osteoporosis, such as rapid bone loss after discontinuation of denosumab (an anti-RANKL antibody),32,33 and attenuation of bone formation markers after starting romosozumab (an anti-SCL antibody).34